Sodium Picosulfate
Colon Carcinoma
Region SkaneSmall moleculePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 65/ 100
Competitive context
153 Active assets in the Colon Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Floxuridine City of Hope Medical Center | Phase 2 | BBB |
Fluorouracilum Akeso | Phase 4 | BB |
Xaliplatin Sun Yat-sen University | Phase 3 | BB |
Pertuzumab IFOM ETS - The AIRC Institute of Molecular Oncology | Phase 3 | BB |
TRASTUZUMAB IFOM ETS - The AIRC Institute of Molecular Oncology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Sodium Picosulfate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →